Why the study?
Does the administration of protease inhibitors alter the postmortem degradation of myofibril proteins in cardiac and skeletal muscle of male Wistar rats?
Does the administration of protease inhibitors alter the postmortem degradation of myofibril proteins in cardiac and skeletal muscle of male Wistar rats?
Postmortem degradation of myofibril proteins is fundamentally similar in cardiac and skeletal muscles but responds differently to specific protease inhibitors.
Answers are grounded in this paper and cite their sources.
Differential protease inhibitor effects on postmortem myofibrillar degradation in rat cardiac versus skeletal muscle; hypothesis-generating for forensic pathology and requires human validation.
To understand the mechanism in postmortem autolysis better, processes in the postmortem degradation of myofibril proteins in the presence of protease inhibitors were studied. Male Wistar rats were given injections of the carboxyl-, thiol-, and serine-protease inhibitors, pepstatin, Ep-475[L-transepoxysuccinyl-leucylamide(3-methyl) butane; E-64-C], and chymostatin, via the femoral vein. Control rats were similarly treated with saline. Then, myofibril proteins were isolated from their cardiac and femoral muscles and from those of control animals at various times after death, and degradation of these myofibril proteins with time was examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In cardiac muscle, alpha-actinin was degraded rapidly, followed by the heavy chain of myosin and light chain of myosin (L2). Actin and the light chain of myosin (L1) were degraded slowly. the degradations of the heavy chain of myosin, alpha-actinin, tropomyosin and L2 after 14 days were not inhibited by pepstatin, but were inhibited by Ep-475 and chymostatin. In skeletal muscle, L1 and L2 were degraded rapidly, followed by the heavy chain of myosin and alpha-actinin. Actin was degraded slowly and was still unchanged 2 weeks after death. The degradations of protein components were inhibited by pepstatin, Ep-475 and chymostatin. These results indicated that after death the components of myofibrils are degraded by various proteases at various rates depending on their properties or structures. This degradation is fundamentally the same in cardiac and skeletal muscles, but inhibitors have somewhat different effects on the postmortem degradation processes after death in the two types of muscle.
No takes yet. Share an insight, caveat, or question.
Tokunaga et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: